|Bid||60.09 x 900|
|Ask||64.00 x 1200|
|Day's range||53.97 - 60.95|
|52-week range||53.97 - 189.89|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||3.19|
|Earnings date||02 Mar 2022 - 07 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||141.00|
Shares of diagnostic testing company Fulgent Genetics (NASDAQ: FLGT) were up 93% last year, according to S&P Global Market Intelligence. The unpredictability of COVID took shareholders on a journey through several peaks and valleys on the way to that gain. The roller coaster has continued into 2022 with the stock down nearly 20% year to date already.
FLGT, LGO, CTRN, and TGH have been selected as the top picks with a high net income ratio.
Read more to see why three Fool.com contributors think COVID stocks Fulgent Genetics (NASDAQ: FLGT), NRx Pharmaceuticals (NASDAQ: NRXP), and Adaptive Biotechnologies (NASDAQ: ADPT) could double your money this year. Will this stock turn on? Patrick Bafuma (Fulgent Genetics): Entering the last wave of 2021, you may have heard that there was a run on COVID tests.